Ascendis Pharma A/S has regained full control of its TransCon technology for metabolic and cardiovascular diseases from Novo Nordisk A/S, including the once-monthly TransCon Semaglutide program, after the companies terminated their collaboration in November 2024. Ascendis plans to initiate multiple programs in the technology area and has authorized a share repurchase of up to $400 million. Shares fell 12.40% to $232.07 at the time of publication, trading below key short- and medium-term moving averages and near the 200-day average. The stock retains a Buy consensus rating with an average price forecast of $319.47, while Benzinga Edge rated its momentum bullish at 84.79 and value weak at 12.4.